You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾輝健康與中山大學完成兩項鼻咽癌篩查相關專利轉讓
格隆匯 12-20 08:58
格隆匯12月20日丨諾輝健康17日宣佈完成兩項鼻咽癌篩查相關專利轉讓,並將在此基礎與中山大學附屬腫瘤醫院賈衞華教授及其團隊合作開發針對鼻咽癌的篩查產品。兩項專利轉讓費用共計1000萬元。“一種鼻咽癌診斷標誌物”和“一種鼻咽刷”的發明人為中山大學腫瘤中心賈衞華教授以及其團隊。中山大學附屬腫瘤醫院是全球領先的鼻咽癌臨牀治療和研究中心。賈衞華教授為中國協和醫科大學流行病學專業醫學博士,現任華南腫瘤學國家重點實驗室首席研究員,長期致力於腫瘤遺傳及基因組學、腫瘤分子流行病學研究,2013年獲得國家自然科學基金傑出青年基金,2014年獲得第十一屆“中國青年女科學家”稱號,2016年入選國家“萬人計劃”科技創新領軍人才。鼻咽癌指發生於鼻咽粘膜上皮的惡性腫瘤,中國南方高發地區的發病率高達20~30/10萬。全球有80%的鼻咽癌患者集中在中國華南和東南亞地區,其中廣東和香港地區發病率居全球第一。早期鼻咽癌的5年生存率超過90%,但晚期鼻咽癌的治療手段不理想,嚴重影響患者生存質量,臨牀迫切需要有效的篩查和治療手段。諾輝健康執行董事兼CEO朱葉青表示,“鼻咽癌篩查產品的開發將結合諾輝健康專有的多組學分子診斷技術平台,通過對多種生物標誌物的聯合檢測實現對鼻咽癌的高靈敏度檢測。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account